Monitoring immune cells after CAR-T therapy for myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma (a type of blood cancer).
- You are scheduled to receive CAR-T cell therapy following standard French guidelines.
- You do not have any serious health issues that could affect your ability to follow the study plan.
- You are not currently in another clinical trial that requires a waiting period.
- You are not pregnant, breastfeeding, or under legal protection (like guardianship).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CAR-T cell therapy given after your own stem cell transplant. It aims to improve the response for multiple myeloma, a type of blood cancer, and is for patients who did not get a complete response after initial chemo or who have high-risk features.
This study looks at blood samples from people with B-cell lymphoma or multiple myeloma who are getting CAR-T cell therapy. The goal is to find signs in the blood that might predict how well the treatment works, which could help improve care for future patients.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This study tests a new type of cell therapy, called CAR-T, for people newly diagnosed with myeloma who can't have a stem cell transplant. The therapy uses your own immune cells, changed in a lab to better fight the myeloma cells.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.